Compare CPIX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPIX | NRXS |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.3M | 78.9M |
| IPO Year | 2007 | 2023 |
| Metric | CPIX | NRXS |
|---|---|---|
| Price | $7.68 | $7.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 48.6K | ★ 128.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.70 | 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,010,949.00 | $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.75 | ★ 32.89 |
| 52 Week Low | $1.85 | $2.21 |
| 52 Week High | $9.28 | $9.33 |
| Indicator | CPIX | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 67.04 |
| Support Level | $7.34 | $6.60 |
| Resistance Level | $8.27 | $7.70 |
| Average True Range (ATR) | 0.46 | 0.48 |
| MACD | 0.12 | 0.18 |
| Stochastic Oscillator | 60.67 | 84.00 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).